Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agensys, an affiliate of Tokyo-based Astellas Pharma, and Seattle Genetics have commenced a Phase I clinical trial to assess the safety, tolerability, pharmacokinetic profile and antitumor activity of escalating doses of ASG-5ME as a treatment of castration-resistant prostate cancer.
Subscribe to our email newsletter
Agensys and Seattle Genetics said that the study is designed to recruit up to 60 patients at multiple centers in the US.
ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed by both companies for the treatment of solid tumors.
Agensys CEO senior vice president and chief medical officer Leonard Reyno said that they believe ASG-5ME, which is an ADC designed to deliver the potent cytotoxic agent MMAE directly to tumor cells, has the potential to provide a new therapeutic option for men with advanced prostate cancer.
Seattle Genetics Research and Translational Medicine senior vice president Jonathan Drachman said that the clinical trial, together with their ongoing phase I trial of ASG-5ME for pancreatic cancer, reflects continued progress in expanding their pipeline of clinical-stage ADCs for cancer.